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Background
The introduction of highly active antiretroviral therapy
(HAART) has resulted in a dramatic decline in the inci-
dence of AIDS-associated Kaposi sarcoma (KS) among
men who have sex with men (MSM). The decline had
been associated with increased CD4+ cell counts; how-
ever, the effect of HAART on the epidemiology of the
Kaposi sarcoma-associated herpesvirus (KSHV) has not
been investigated. We describe here the prevalence of
KSHV in HIV infected and uninfected MSM across time
periods of different prevailing HAART usage.
Subjects, materials, and methods
The serostatus of 4159 participants in the prospective
Multicenter AIDS Cohort Study (MACS) was ascertained
using two ELISAs, detecting antibodies against the latently
associated nuclear antigen (LANA) and the lytic antigen
encoded by ORFk8.1, respectively. KSHV seropositivity
was defined as positivity in either assay. The calendar per-
iod between 1984 and 1990 was defined as untreated era,
while the periods 1990-1995 and 1995-2001 were defined
as pre-HAART era and HAART era, respectively. Because
the last wave of enrollment in the MACS that occurred in
2001 involved a distinct change in study demographics, a
fourth period, 2001-2009 was defined as current era.
Results
The study population was composed of 2920 HIV-posi-
tive and 1239 HIV-negative subjects. The prevalence of
KSHV was 54.6% overall (95% CI: 53.0-56.1%), 67.8%
(95% CI: 66.0-69.5%), in HIV+ and 23.5% (95% CI: 21.1-
25.9%) in HIV- subjects. When examining the cohort by
calendar time, the prevalence was 52.9% (95% CI: 51.2-
54.6%) in the untreated era, 67.5% (95% CI: 59.3-75.1%)
in the pre-HAART era, 52.7% (95% CI: 35.4-69.9%) in the
HAART era, and 59.7% (56.0-63.4%) in the current era.
Conclusions
The overall prevalence of KSHV in MSM enrolled in the
MACS did not vary significantly from 1984 through 2009,
indicating that the decline in incidence of KS seen over
the same calendar periods in this population is not asso-
ciated with a decline in KSHV prevalence. The observation
is significant because of the potential excess morbidity risk
associated with KSHV in an aging population, particularly
among HIV/ KSHV co-infected individuals, notwithstand-
ing effective anti-HIV treatment. To elucidate the
mechanisms sustaining the high prevalence of KSHV
amongst MSM, KHSV incidence in time and risk factors
associated with KSHV infection are being investigated.
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